Bortezomib, Lenalidomide, and Dexamethasone ± Elotuzumab in Patients With Untreated, High-Risk Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Haematology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Bortezomib, Lenalidomide, and Dexamethasone With or Without Elotuzumab in Patients With Untreated, High-Risk Multiple Myeloma (SWOG-1211): Primary Analysis of a Randomised, Phase 2 Trial
Lancet Haematol 2021 Jan 01;8(1)e45-e54, SZ Usmani, A Hoering, S Ailawadhi, R Sexton, B Lipe, SF Hita, J Valent, M Rosenzweig, JA Zonder, M Dhodapkar, N Callander, T Zimmerman, PM Voorhees, B Durie, SV Rajkumar, PG Richardson, RZ OrlowskiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.